Targeting a protein to improve joint health after injuries
Sustained Biomaterial-mediated Inhibition of R-spondin 2 to Target Pathological Wnt Signaling in Post-Traumatic Osteoarthritis
This study is looking at how a special substance called R-spondin 2 can help treat post-traumatic osteoarthritis (PTOA) by using tiny beads that release a medication called Mianserin directly into the joint, aiming to make your joints feel better and work well again.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10865059 on NIH RePORTER |
What this research studies
This research investigates the role of R-spondin 2 in post-traumatic osteoarthritis (PTOA) and aims to develop a new treatment using biomaterials to deliver a drug called Mianserin. The approach involves creating microspheres made from a biocompatible material that can release Mianserin directly into the joint, inhibiting harmful signaling pathways that contribute to joint degeneration. By focusing on sustained delivery, the researchers hope to provide a more effective treatment for patients suffering from PTOA. The study will validate the effectiveness of this method in reducing symptoms and improving joint health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with post-traumatic osteoarthritis, particularly those experiencing significant joint pain and degeneration following an injury.
Not a fit: Patients with osteoarthritis not related to trauma or those with other underlying joint conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that significantly alleviates pain and improves joint function for patients with post-traumatic osteoarthritis.
How similar studies have performed: While the specific approach of using Mianserin-loaded biomaterials is novel, similar strategies targeting Wnt signaling have shown promise in other studies.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Maerz, Tristan — University of Michigan at Ann Arbor
- Study coordinator: Maerz, Tristan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.